BR0006823A - Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial - Google Patents

Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial

Info

Publication number
BR0006823A
BR0006823A BR0006823-3A BR0006823A BR0006823A BR 0006823 A BR0006823 A BR 0006823A BR 0006823 A BR0006823 A BR 0006823A BR 0006823 A BR0006823 A BR 0006823A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
polypeptide compound
cyclic polypeptide
injection preparation
commercial package
Prior art date
Application number
BR0006823-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Seiji Sawai
Akihiro Kasai
Kazumi Otomo
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0006823(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR0006823A publication Critical patent/BR0006823A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR0006823-3A 1999-07-01 2000-06-29 Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial BR0006823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18771399 1999-07-01
PCT/JP2000/004381 WO2001002002A1 (en) 1999-07-01 2000-06-29 Stabilized pharmaceutical composition in lyophilized form

Publications (1)

Publication Number Publication Date
BR0006823A true BR0006823A (pt) 2001-06-05

Family

ID=16210881

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0006823-3A BR0006823A (pt) 1999-07-01 2000-06-29 Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial
BRPI0006823A BRPI0006823B8 (pt) 1999-07-01 2000-06-29 composição farmacêutica estabilizada, preparação de injeção, e kit comercial

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0006823A BRPI0006823B8 (pt) 1999-07-01 2000-06-29 composição farmacêutica estabilizada, preparação de injeção, e kit comercial

Country Status (28)

Country Link
US (2) US6774104B1 (enExample)
EP (1) EP1107777B1 (enExample)
JP (2) JP3381722B2 (enExample)
KR (1) KR100454784B1 (enExample)
CN (2) CN100352495C (enExample)
AR (1) AR024634A1 (enExample)
AT (1) ATE280583T1 (enExample)
AU (1) AU752265B2 (enExample)
BR (2) BR0006823A (enExample)
CA (1) CA2341568C (enExample)
CZ (1) CZ295720B6 (enExample)
DE (1) DE60015279T2 (enExample)
ES (1) ES2225161T3 (enExample)
HK (1) HK1040057B (enExample)
HU (1) HU229089B1 (enExample)
ID (1) ID29468A (enExample)
IL (2) IL141455A0 (enExample)
MX (1) MXPA01000601A (enExample)
NO (1) NO330353B1 (enExample)
NZ (1) NZ510290A (enExample)
OA (1) OA11601A (enExample)
PL (1) PL200141B1 (enExample)
PT (1) PT1107777E (enExample)
RU (1) RU2251411C2 (enExample)
TR (1) TR200100609T1 (enExample)
TW (1) TWI233805B (enExample)
WO (1) WO2001002002A1 (enExample)
ZA (1) ZA200101589B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
EP1525884B1 (en) 2002-07-31 2011-10-12 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
HUE041133T2 (hu) * 2002-11-18 2019-05-28 Vicuron Pharmaceuticals Llc Dalbavancin adagolási módszer bakteriális fertõzések kezelésére
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
AU2005219090B2 (en) * 2004-03-04 2008-01-10 Eisai R&D Management Co., Ltd Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
JP2007538046A (ja) * 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ 新規なアザビシクロアリール誘導体
KR20070109985A (ko) * 2004-11-22 2007-11-15 아나디스 리미티드 생물활성 조성물
KR101307999B1 (ko) * 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
CN101228442B (zh) * 2005-07-20 2013-03-27 协和梅迪克斯株式会社 生物样品中肽的稳定方法
CN1962852B (zh) * 2006-11-27 2011-11-09 西北农林科技大学 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
PE20150683A1 (es) * 2012-05-22 2015-06-03 Paion Uk Ltd Composiciones que comprenden benzodiazepinas de accion corta
EP2893929B1 (en) 2013-03-15 2025-04-16 Merck Sharp & Dohme LLC Ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
CN103330932B (zh) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 一种米卡芬净或其盐的药物组合物
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
SG11201510003VA (en) * 2013-06-05 2016-01-28 Univ British Columbia Anti-fibrogenic compounds, methods and uses thereof
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101611349B1 (ko) 2014-04-14 2016-04-12 신우철 안정성이 개선된 밀크씨슬 엑스의 제형
CN104861043B (zh) * 2014-05-29 2019-03-01 上海天伟生物制药有限公司 一种环肽类化合物的组合物及其制备方法和用途
RU2732129C2 (ru) * 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
DK3240529T3 (da) * 2014-12-31 2022-02-28 Galenicum Health S L U Stabile farmaceutiske sammensætninger omfattende micafungin
ES2694561T3 (es) 2015-02-23 2018-12-21 Selectchemie Ag Composición de anidulafungina
AU2017376960B2 (en) 2016-12-16 2023-12-14 Baxter Healthcare Sa Micafungin compositions
WO2019005829A1 (en) * 2017-06-26 2019-01-03 Wayne State University METHODS AND COMPOSITIONS RELATING TO CANCER DEPENDENT ON HORMONE RECEPTORS
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
IE912046A1 (en) * 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
RU2095081C1 (ru) * 1991-12-13 1997-11-10 Акционерное общество "Биофа" Фармацевтическая композиция антивирусного действия
JPH0651641A (ja) 1992-07-30 1994-02-25 Olympus Optical Co Ltd 湿式現像装置
JPH06172204A (ja) * 1992-12-09 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja) 1993-02-25 2001-12-25 ソニー株式会社 偏平型陰極線管の画像歪補正装置
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
AU681119B2 (en) * 1993-05-17 1997-08-21 Fujisawa Pharmaceutical Co., Ltd. New polypeptide compound and a process for preparation thereof
MX9702531A (es) 1994-10-07 1997-06-28 Fujisawa Pharmaceutical Co Compuesto nuevo.
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
CA2248348C (en) * 1996-03-08 2008-06-10 Fujisawa Pharmaceutical Co., Ltd. Process for the deacylation of cyclic lipopeptides
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
JPH09301997A (ja) 1996-05-17 1997-11-25 Yamanouchi Pharmaceut Co Ltd 新規環状ペプチド系化合物
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JPH10279498A (ja) * 1997-04-07 1998-10-20 Nippon Shinyaku Co Ltd 慢性関節リウマチ治療剤
JP3544847B2 (ja) * 1998-01-16 2004-07-21 三菱電機株式会社 光学的情報再生方法および装置
HK1040369A1 (zh) * 1999-03-03 2002-06-07 Eli Lilly And Company 制备药物口服ecb配方和组合物的方法
ES2433678T3 (es) * 1999-03-03 2013-12-12 Eli Lilly & Company Formulaciones farmacéuticas de equinocandina que contienen tensioactivos formadores de micelas
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent

Also Published As

Publication number Publication date
IL141455A (en) 2006-12-31
NO20010893D0 (no) 2001-02-22
ATE280583T1 (de) 2004-11-15
BRPI0006823B1 (pt) 2020-01-07
HK1080724A1 (zh) 2006-05-04
US20040157769A1 (en) 2004-08-12
ZA200101589B (en) 2002-09-02
IL141455A0 (en) 2002-03-10
CN1636591A (zh) 2005-07-13
ES2225161T3 (es) 2005-03-16
US6774104B1 (en) 2004-08-10
HUP0103740A3 (en) 2002-08-28
OA11601A (en) 2004-07-30
JP4691866B2 (ja) 2011-06-01
BRPI0006823B8 (pt) 2021-05-25
MXPA01000601A (es) 2002-04-08
NO330353B1 (no) 2011-04-04
ID29468A (id) 2001-08-30
CN1315865A (zh) 2001-10-03
CN100352495C (zh) 2007-12-05
AU752265B2 (en) 2002-09-12
KR20010072903A (ko) 2001-07-31
HUP0103740A2 (hu) 2002-02-28
KR100454784B1 (ko) 2004-11-05
JP2002363097A (ja) 2002-12-18
EP1107777B1 (en) 2004-10-27
RU2251411C2 (ru) 2005-05-10
DE60015279D1 (de) 2004-12-02
CN1179748C (zh) 2004-12-15
US7112565B2 (en) 2006-09-26
DE60015279T2 (de) 2005-05-25
HU229089B1 (en) 2013-07-29
PT1107777E (pt) 2005-01-31
JP3381722B2 (ja) 2003-03-04
NO20010893L (no) 2001-04-24
CA2341568A1 (en) 2001-01-11
CA2341568C (en) 2011-10-25
EP1107777A1 (en) 2001-06-20
PL200141B1 (pl) 2008-12-31
CZ20011186A3 (cs) 2001-09-12
TR200100609T1 (tr) 2001-07-23
PL346297A1 (en) 2002-01-28
HK1040057A1 (en) 2002-05-24
WO2001002002A1 (en) 2001-01-11
NZ510290A (en) 2003-07-25
CZ295720B6 (cs) 2005-10-12
AU5572200A (en) 2001-01-22
HK1040057B (zh) 2005-08-05
AR024634A1 (es) 2002-10-16
JP2003503462A (ja) 2003-01-28
TWI233805B (en) 2005-06-11

Similar Documents

Publication Publication Date Title
BR0006823A (pt) Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BRPI9908319A (pt) composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo.
BR0213877A (pt) Compostos orgânicos
IL123164A (en) Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them
BR9814832A (pt) Composto, e, herbicida
BR9806413A (pt) Composto e uso do mesmo
NO973923D0 (no) Nye taxoider, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
KR870700620A (ko) 신규 약리학적 화합물
BR0010520A (pt) Novos compostos farmaceuticamente ativos
FR2677984B1 (fr) Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
BR0108677A (pt) Novos compostos
DE69932424D1 (de) Melanocortin 1 rezeptorselektive verbindungen
NO20021859L (no) Nye oligosakkarider, deres fremstilling samt farmasöytiske preparater inneholdende oligosakkaridene
BR0209452A (pt) Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto
BR9712140A (pt) Agentes e processos para inibir a produção de citoquina, a adesão de cédulas e a produção de tnf - alfa e uso de um composto.
BR9913183A (pt) Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica
NO983691L (no) Forbindelser tilh°rende amidiniumfamilien, farmas°ytiske preparater inneholdende disse samt anvendelse derav
NO974563D0 (no) Nye taxoider, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
KR880011112A (ko) 벤즈아제핀 설폰아미드 화합물
WO1999033825A8 (en) N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them
DK0447116T3 (da) Urinstof-derivater, deres fremstilling samt lægemidler indeholdende sådanne derivater
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos
EP0266060A3 (en) Cephalosporins, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/06/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/06/2020